Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07591090 | A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer | recruiting | Phase 2 | 200 | AkesoINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03048942 | Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer(CONCEPT) | completed | Phase 2 | 158 | University Hospitals Bristol and Weston NHS Foundation TrustOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04348747 | Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | recruiting | Phase 2 | 23 | Roswell Park Cancer InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04537286 | First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients | completed | Phase 2 | 90 | Fudan UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05297617 | Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk(LESS) | recruiting | Phase 2 | 696 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05618613 | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer(ELONA) | terminated | Phase 1 / Phase 2 | 4 | Context Therapeutics Inc.INDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06450314 | Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.(HEROES) | recruiting | Phase 2 | 170 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07716046 | Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer(FACET) | not yet recruiting | Phase 2 | 240 | Fudan UniversityOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT03414658 | The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | active not recruiting | Phase 2 | 100 | Adrienne G. WaksOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04758780 | Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer(OPALESCENCE) | completed | Phase 2 | 12 | Institut Cancerologie de l'OuestOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04230109 | Sacituzumab Govitecan In TNBC(NeoSTAR) | recruiting | Phase 2 | 239 | Massachusetts General HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04542135 | Sulindac and Breast Density in Women at Risk of Developing Breast Cancer | completed | Phase 2 | 61 | Alison StopeckOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06439771 | A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC | recruiting | Phase 2 | 180 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 67 | University of California, IrvineOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07661927 | Skipping Hormone Therapy in Low-Risk Early Breast Cancer(NoELA) | recruiting | Phase 2 | 700 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04115306 | Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer(Dauntless-1) | active not recruiting | Phase 1 / Phase 2 | 61 | Phoenix Molecular DesignsINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06555068 | A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 528 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06640881 | Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial(REPEAT) | recruiting | Phase 2 | 25 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708194 | Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure | recruiting | Phase 1 / Phase 2 | 94 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02411656 | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | active not recruiting | Phase 2 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02912312 | Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer | active not recruiting | Phase 2 | 805 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06465368 | A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause | completed | Phase 2 | 121 | PfizerINDUSTRY | 13 | Jul 15, 2026 | clinicaltrials |
| NCT07182721 | SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment(SHINE-HER) | recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04039230 | Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. | active not recruiting | Phase 1 / Phase 2 | 75 | Massachusetts General HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06433609 | Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer | recruiting | Phase 2 | 113 | Beijing GoBroad HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06538389 | High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer | suspended | Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06964906 | Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer(NeoHunter) | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07701941 | A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 220 | Daiichi SankyoINDUSTRY | 0 | Jul 14, 2026 | clinicaltrials |
| NCT04443348 | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | active not recruiting | Phase 2 | 120 | Laura M. Spring, MDOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06970912 | ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer(DNADalHR) | recruiting | Phase 2 | 393 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06976944 | Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer(PRELUDE) | recruiting | Phase 2 | 24 | Yukinori OzakiOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07117630 | An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07366112 | CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment(DNACDKHR) | recruiting | Phase 2 | 158 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07697443 | Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects | not yet recruiting | Phase 1 / Phase 2 | 306 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT01463072 | Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 2 | 40 | City of Hope Medical CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT02364557 | Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival | completed | Phase 2 / Phase 3 | 129 | NRG OncologyOTHER | 4 | Jul 10, 2026 | clinicaltrials |
| NCT03180294 | Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer | completed | Phase 2 | 230 | NRG OncologyOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04711824 | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases(SOLARA) | active not recruiting | Phase 1 / Phase 2 | 41 | Colette ShenOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05101096 | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors(ASCENT-J02) | active not recruiting | Phase 1 / Phase 2 | 135 | Gilead SciencesINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05458674 | Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | active not recruiting | Phase 2 | 17 | Criterium, Inc.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05534438 | A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | recruiting | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07681297 | Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease(TIBEC) | not yet recruiting | Phase 1 / Phase 2 | 154 | National University Hospital, SingaporeOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07694986 | Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD | recruiting | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 22, 2026source: clinicaltrials